Hedge funds cut NFLX, keep big bets on MSFT, AMZN, add NVDA
Major shareholders of Aveanna Healthcare Holdings , Inc. (NASDAQ:AVAH) have recently executed significant stock sales. According to the latest SEC filing, J.H. Whitney VII, L.P., PSA Healthcare Investment Holding LLC, and PSA Iliad Holdings LLC sold shares totaling $735,176. The transactions occurred at prices ranging from $5.46 to $5.51 per share. The stock has shown remarkable strength with a 117% return over the past year and a market capitalization of $1.06 billion. InvestingPro analysis reveals analyst price targets ranging from $4.50 to $7.00. These sales were conducted under a pre-established Rule 10b5-1 trading plan, adopted in December 2024. Following these transactions, the shareholders still hold substantial positions in the company. While currently unprofitable, analysts tracked by InvestingPro expect the company to return to profitability this year, with three analysts recently revising their earnings estimates upward.
In other recent news, Aveanna Healthcare Holdings Inc. reported better-than-expected financial results for the fourth quarter of 2024. The company achieved earnings per share (EPS) of $0.05, surpassing the anticipated loss of $0.003. Revenue also exceeded forecasts, reaching $519.9 million compared to the expected $499.07 million. This performance highlights Aveanna’s strategic focus on enhancing service offerings and expanding payer agreements. The company’s Private Duty Services segment experienced significant growth, increasing by 10.1% year-over-year. Aveanna projects its 2025 revenue to be between $2.100 billion and $2.120 billion, with adjusted EBITDA expected to range from $190 million to $194 million. On the analyst front, UBS raised its price target for Aveanna Healthcare to $4.50 but maintained a Sell rating on the company’s shares. These developments underscore Aveanna’s robust financial health and strategic initiatives aimed at driving future growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.